LONDON, Aug. 17, 2016 /PRNewswire/ -- Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or a condition called maldigestion. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. Management of EPI is based primarily on pancreatic enzyme replacement therapy (PERT), but could also include lifestyle modifications and vitamin supplementation as appropriate. Increase in prevalence of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis accentuates the demand for exocrine pancreatic insufficiency market worldwide. The most effective treatment for exocrine pancreatic insufficiency is to successfully treat the underlying condition causing the enzyme insufficiency. Chronic pancreatitis is a benign disease often characterized by recurrent episodes of abdominal pain supplemented by progressive pancreatic exocrine and endocrine insufficiency. Treatment with antioxidants may improve quality of life and reduce pain in patients suffering from chronic pancreatitis.
This research study analyzes the market for exocrine pancreatic insufficiency (EPI) in terms of revenue (US$ Mn). The exocrine pancreatic insufficiency (EPI) market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. The report also includes key market dynamics, such as drivers, restraints, and opportunities, affecting the demand for exocrine pancreatic insufficiency (EPI) treatment products globally. Comparative analysis has also been included in the executive summary that resembles the percentage market share of each regions in 2014 and 2023 respectively.
This report provides in-depth analysis of the exocrine pancreatic insufficiency market. The stakeholders for this report include companies involved in the manufacturing of products used in treatment of exocrine pancreatic insufficiency. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions.
The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the exocrine pancreatic insufficiency market in the current and future scenario. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the exocrine pancreatic insufficiency market. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.
The exocrine pancreatic insufficiency market by therapeutic has been segmented as pancreatic enzyme replacement therapy (PERT) drugs and diagnostic tests. PERT drugs involves Creon, Zenpep, Pancreaze, Ultresa and Pertzye. The diagnostic tests involves blood tests, endoscopic ultra-sonography, magnetic resonance imaging and CT scanning.
Geography wise, the exocrine pancreatic insufficiency market has been differentiated into five major regions: North America, Asia Pacific, Europe, Latin America and Rest of the World. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., Japan China, Russia, Brazil, Mexico and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the exocrine pancreatic insufficiency market in various regions has been provided in this section.
The report provides market estimation of exocrine pancreatic insufficiency market in terms of revenue (US$ Mn) for all the segments and sub segments with CAGR % for period 2015 to 2023, considering 2014 as the base year. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2014.
The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Abbvie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. are among others.
The global exocrine pancreatic insufficiency market is segmented into the following categories:
Global Exocrine Pancreatic Insufficiency Market, by Therapeutics
Pancreatic Enzyme Replacement Therapy (PERT) Drugs
Creon
Zenpep
Pancreaze
Ultresa
Viokace
Pertzye
Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Sollpura (Liprotamase)
Global Exocrine Pancreatic Insufficiency Market, by Diagnostic Tests
Blood Tests
Endoscopic Ultra-Sonography (EUS)
Magnetic Resonance Imaging (MRI)
CT Scanning
Global Exocrine Pancreatic Insufficiency Market, by Geography
North America
U.S.
Canada
Rest of North America
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
China
Japan
Rest of APAC
Latin America
Brazil
Mexico
Rest of LATAM
Rest of the World
South Africa
Russia
Rest of RoW
Download the full report: https://www.reportbuyer.com/product/4042051/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exocrine-pancreatic-insufficiency-market---and-phase-iii-drugs-diagnostic-test---blood-tests-endoscopic-ultra-sonography-mri-and-ct-scanning---global-industry-analysis-size-share-growth-trends-and-forecast-2013---2023-300315120.html
SOURCE ReportBuyer
Share this article